Intranasal delivery of stem cells labeled by nanoparticles in neurodegenerative disorders: Challenges and opportunities.
Mahmoudreza HadjighassemAlimohamad AsghariFarzad Taghizadeh-HesarySalah MoradiMohammad FarhadiMehdi MehdizadehSara SimorghAlireza NourazarianBehrouz ShademanAlireza SusanabadiKamran KamravaPublished in: Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology (2023)
Neurodegenerative disorders occur through progressive loss of function or structure of neurons, with loss of sensation and cognition values. The lack of successful therapeutic approaches to solve neurologic disorders causes physical disability and paralysis and has a significant socioeconomic impact on patients. In recent years, nanocarriers and stem cells have attracted tremendous attention as a reliable approach to treating neurodegenerative disorders. In this regard, nanoparticle-based labeling combined with imaging technologies has enabled researchers to survey transplanted stem cells and fully understand their fate by monitoring their survival, migration, and differentiation. For the practical implementation of stem cell therapies in the clinical setting, it is necessary to accurately label and follow stem cells after administration. Several approaches to labeling and tracking stem cells using nanotechnology have been proposed as potential treatment strategies for neurological diseases. Considering the limitations of intravenous or direct stem cell administration, intranasal delivery of nanoparticle-labeled stem cells in neurological disorders is a new method of delivering stem cells to the central nervous system (CNS). This review describes the challenges and limitations of stem cell-based nanotechnology methods for labeling/tracking, intranasal delivery of cells, and cell fate regulation as theragnostic labeling. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease.
Keyphrases
- stem cells
- cell therapy
- drug discovery
- multiple sclerosis
- healthcare
- end stage renal disease
- chronic kidney disease
- primary care
- spinal cord
- ejection fraction
- physical activity
- mesenchymal stem cells
- working memory
- high dose
- risk assessment
- prognostic factors
- oxidative stress
- quality improvement
- mild cognitive impairment